Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q2 2023 Earnings Call Transcript
Operator: Good morning, everyone. And welcome to the Deciphera Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. Today’s call is being recorded.
Deciphera Pharmaceuticals Inc. (DCPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 6,897,606 | $87,737,548 | +3% | 1.93% |
| 2. | Armistice Capital Steven Boyd | 4,612,000 | $58,664,640 | +2% | 0.89% |
| 3. | Redmile Group Jeremy Green | 4,475,384 | $56,926,884 | -9% | 2.7% |
| 4. | Braidwell LP Alex Karnal | 3,336,221 | $42,436,731 | -9% | 1.34% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,750,000 | $22,260,000 | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.88 | 10,000 | Director | 10,000 | 2023-06-08 | Filing | |
| $13.86 | 11,000 | Director | 11,000 | 2023-05-10 | Filing | |
| $18.00 | 1,666,666 | Large Shareholder | 19,718,014 | 2023-01-24 | Filing | |
| $10.00 | 1,478,978 | Large Shareholder | 18,051,348 | 2022-04-29 | Filing | |
| $17.00 | 375,000 | Large Shareholder | 2,146,308 | 2017-10-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.57 | 17,801 | 45,435 | 2023-11-30 | Filing | ||
| $12.02 | 2,360 | Officer | 90,628 | 2023-10-30 | Filing | |
| $12.02 | 1,407 | Officer | 48,283 | 2023-10-30 | Filing | |
| $12.02 | 1,407 | Officer | 62,884 | 2023-10-30 | Filing | |
| $12.02 | 2,316 | Officer | 63,068 | 2023-10-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,449,006 | $69,311,356 | 0% | |
| 2. | 4,368,433 | $55,566,467 | 0% | |
| 3. | 2,311,118 | $29,397,421 | 0% | |
| 4. | 2,016,507 | $25,649,969 | 0% | |
| 5. | 1,592,985 | $20,262,771 | 0% |
News See All
5 Best Small Cap Pharma Stocks to Buy
In this piece, we will take a look at the five best small cap pharma stocks to buy.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q1 2023 Earnings Call Transcript
Operator: Good morning, everyone, and welcome to Deciphera Pharmaceuticals First Quarter 2023 Financial Results Conference Call. Later, we will conduct a question-and-answer session.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2022 Earnings Call Transcript
Operator: Good morning, everyone, and welcome to Deciphera Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Bill Ackman, Anthony Scaramucci, Ken Griffin, Skylar Capital Management, K2 Advisors, First Financial Bankshares Inc (FFIN), Deciphera Pharmaceuticals, Inc. (DCPH), and More
Pershing Square CEO Bill Ackman said Hindenburg Research’s report about Gautam Adani’s corporate empire Adani Group is "highly credible" and "extremely well-researched".
Here is What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH)
A whopping number of 13F filings filed with U.S.
5 Best Fast Growth Stocks to Buy Now
Revolve Group, Inc. (NYSE:RVLV) is an online fashion retailer.
5 Pharmaceutical Stocks to Buy Under $20 According to Jeremy Green's Redmile Group
In this article, we discuss the 5 pharmaceutical stocks to buy under $20 according to Jeremy Green's Redmile Group portfolio based on Q3 holdings of the fund.
Deciphera Pharmaceuticals, Inc. (DCPH) Fell Out Of Favor With Hedge Funds?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
15 Stocks that Will Double In 2021
The economy of 2020 was closely linked to the COVID-19 pandemic. However, the vaccine rollout at the turn of the year buoyed hopes of a return to normalcy and an accelerated recovery from the virus.
Billionaire Hedge Funds
